X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Company plans to use the proceeds towards the development of its pipeline of allogeneic CAR T-cell product candidates, UCART22, UCART20x22, and UCART123.
Lead Product(s): UCART22
Therapeutic Area: Oncology Product Name: UCART22
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: European Investment Bank
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing January 16, 2024
Details:
AstraZeneca will leverage Cellectis proprietary gene editing technologies to design novel cell and gene therapy products. Under the agreement, 25 genetic targets have been reserved for AstraZeneca, from which up to 10 candidates could be explored for development.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $945.0 million Upfront Cash: $105.0 million
Deal Type: Collaboration November 01, 2023
Details:
UCART22 is one of Cellectis’ wholly owned, allogeneic, off-the-shelf gene-edited T-cell product candidates designed for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
Lead Product(s): UCART22,Alemtuzumab
Therapeutic Area: Oncology Product Name: UCART22
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2023
Details:
The Company plans to use the proceeds towards the development of its pipeline of allogeneic CAR T-cell product candidates: UCART22, UCART20x22, UCART123 and UCARTCS1.
Lead Product(s): UCART22,Alemtuzumab
Therapeutic Area: Oncology Product Name: UCART22
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: European Investment Bank
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 04, 2023
Details:
Allogeneic CAR T-cells with specific attributes to locally release immune inflammatory cytokines and protect from inhibitory effects of the TGFB1 and PD1 pathways. It is being evaluated against TNBC tumors in various in vivo pre-clinical models.
Lead Product(s): Allogeneic MUC-1 CAR T-cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
The Company plans to use the net proceeds to fund the continued clinical development of UCART 123, UCART22, UCART20x22, and UCARTCS1, and any remainder for working capital and other general corporate purposes.
Lead Product(s): UCART123v1.2
Therapeutic Area: Oncology Product Name: UCART123
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Jefferies LLC
Deal Size: $24.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 07, 2023
Details:
Cellectis plans to use the net proceeds to fund the continued clinical development of UCART123, UCART22, UCART20x22, and UCARTCS1. UCART123v1.2, is a gene-edited T-cell investigational drug that targets CD123, an antigen expressed at the surface of leukemic cells in AML.
Lead Product(s): UCART123v1.2
Therapeutic Area: Oncology Product Name: UCART123
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Jefferies LLC
Deal Size: $22.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 02, 2023
Details:
Under the partnership, Cytovia will be responsible for the differentiation and expansion of the gene-edited iPSC-derived NK Cells and will conduct the pre-clinical evaluation, clinical development, and commercialization of the selected therapeutic candidates.
Lead Product(s): Gene-edited iPSC-derived NK Cell
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cytovia Therapeutics
Deal Size: $825.0 million Upfront Cash: $20.0 million
Deal Type: Collaboration January 20, 2023
Details:
Primera is advancing pioneering mtDNA gene editing therapies developed in the Mayo Clinic lab to precisely fix a patient’s mutated mtDNA and potentially achieve a cure for the disease.
Lead Product(s): mtDNA-based Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Primera Therapeutics
Deal Size: $750.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 29, 2022
Details:
UCART22 is an allogeneic CAR T-cell product candidate that targets CD22 and is evaluated in the BALLI-01 clinical study, designed to evaluate the safety and clinical activity of the product candidate in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Lead Product(s): UCART22
Therapeutic Area: Oncology Product Name: UCART22
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
